VivoSeq
Oncology

Lymphoma, Large B-Cell, Diffuse

9

Pipeline Programs↗

1

Active Trials↗

4

Companies Involved↗

Lymphoma, Large B-Cell, Diffuse is an early-stage landscape with 9 programs across 4 companies. The most active players are Merck & Co., Roche, Pfizer.

Intelligence

Pipeline Metrics

Competitive Density

35/100

Pipeline Velocity

0/100

Mech. Concentration

40/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

3 programs

Phase 2Roche logo

Roche

2 programs

Phase 2Pfizer logo

Pfizer

1 program

Phase 2P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 29

Zilovertamab Vedotin

Merck & Co.

Rituximab

Roche

Cyclophosphamide

Baxter Healthcare Corporation

Doxorubicin

Pfizer

Rituximab Biosimilar

Merck & Co.

Phase 3
No programs
Approved
No programs

Analysis

Modality Breakdown

7programs
Small molecule457%
Antibody–drug conjugate229%
Monoclonal antibody114%

Modality classified for 78% of 9 pipeline programs.

Analysis

Trial Status

1

clinical trials

Recruiting1 · 100%

Clinical Trials

Trial Activity

A Randomized, Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-naïve Participants With GCB Subtype of Diffuse Large B-cell Lymphoma (DLBCL)
Recruiting·Merck & Co. logoMerck & Co.·Phase 2·NCT06890884·594 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)